Biosimilars, also known as follow-on biologics, are the subsequent versions of innovative biological medicine that are introduced after the expiry of the original medicine's patent. The development of biosimilars is a complex and expensive process, but it has potential to improve the accessibility of life-saving treatments. Emerging technological trends in the biosimilar sector are redefining the way these medicines are developed, evaluated, and marketed. Given that India is a global hub for generic medicine, it is critical to examine the country's role in the rapidly evolving biosimilars landscape.
In recent years, the market for biosimilars or similar biologics, has seen significant expansion, particularly in India. India's biosimilars market size was valued at $349 million in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 25.2 per cent from 2022 to 2030 and will reach $2108 million by 2030.
India is one of the leading manufacturers of biosimilars, and has observed an increase in their use, improving the health of many patients suffering from a wide variety of diseases. The most significant advantage of biosimilars is that they cost less than the original drugs that they replicate.
An article noted that the expiration of patents on many key biologics by 2020 would provide a sizable opportunity for the development and use of biosimilars. With over one hundred biopharmaceutical companies engaged in the manufacturing and marketing of biosimilars, India has emerged as a global market leader in this segment. It was the first to approve a biosimilar back in 2000 for the treatment of hepatitis B- much before Europe and the United States.
Bu hikaye Bio Spectrum dergisinin August 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Bio Spectrum dergisinin August 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Amit Agrawal steps in as new Pharmaceuticals Secretary
Amit Agrawal, the Chief Executive Officer (CEO) of the Unique Identification Authority of India (UIDAI), has been appointed as the new Secretary of the Department of Pharmaceuticals, Government of India.
IIT-B joins hands with Tohoku University to offer MTech, PhD dual degree programmes
The Indian Institute of Technology, Bombay (IIT-B) has entered into a Memorandum of Understanding (MoU) with Japan's Tohoku University to launch the IIT Bombay-Tohoku University Joint Academic & Research Programme.
Innovative injectable hydrogel to offer targeted breast cancer therapy
In a multi-institutional research led by researchers from Indian Institute of Technology Guwahati (IIT-G) and Bose Institute Kolkata, an advanced injectable hydrogel has been developed for localised cancer treatment.
Bio-Techne, Waters ink co-marketing agreement for biotherapeutic characterisation
American life sciences company Bio-Techne Corporation, a leader in automated platforms for biotherapeutic characterisation, has announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterisation and development processes.
Nano-formulation of darkness hormone to serve as therapeutic solution for Parkinson's disease
Scientists from Institute of Nano Science and Technology (INST) Mohali have proved that nano-formulation of Melatonin, the hormone produced by the brain in response to darkness, showed improved antioxidative and neuroprotective properties and could be a potential therapeutic solution for Parkinson's disease (PD).
"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"
\"In a recent development, Nagpur-based biotech company GeNext Genomics (GNG) has joined -hands with Merck Life Science to support the Indian biotech system, particularly in the area of biomanufacturing, which is garnering more attention after the approval of the BioE3 policy.Supriya Kashikar, Founder & Chief Executive Officer, GeNext Genomics shares her views with BioSpectrum on the growth of biomanufacturing sector in India, and how the company plans to play a relevant role in this aspect.
Redcliffe Labs reinforces strategic leadership as Aditya Kandoi steps into CEO role, Dheeraj Jain as Chairman
Redcliffe Labs, a purpose-driven pan-India omnichannel diagnostics service provider, has announced a strategic leadership transition.
Zyla Health on-boards Rohit Boda as Advisor
Gurugram-based Zyla Health, a care management platform, has announced the onboarding of renowned industry leader, Rohit Boda, to the Board of Advisors.
Claypond Capital appoints Shravan Subramanyam to lead medtech platform
Claypond Capital, the family investment office of Dr Ranjan Pai, has announced the appointment of Dr Shravan Subramanyam as the head of its medical technology platform.
How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry
India's life sciences sector is undergoing a major transformation, led by the expansion of Global Capability Centres GCCs). These centres, which serve as strategic hubs for multinational companies in pharmaceuticals, biotechnology, and healthcare, are strengthening India's role in the global life sciences landscape. Currently, there are over 95 life sciences GCCs in India, employing approximately 280,000 professionals. By 2030, this number is projected to reach 160 GCCs and around 420,000 employees. Advancements in artificial intelligence AI) are central to this transformation, driving innovation across drug discovery and clinical research. India's life sciences GCCs have evolved from operational support centres to world-class R&D engines, leveraging India’s robust talent pool, advanced technology adoption, and cost advantages. These GCCs are driving the future of Al-powered drug discovery and clinical research. Let’s explore further.
